Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
HBP.TO Interest Expense
Cost of servicing the company's debt during the period.
Helix BioPharma Corp.TSX: HBP.TO
Interest Expense · Q3 FY2026 · quarter ended Apr 2026
Interest expense growth accelerates
Q3 FY2026 interest expense of CA$7K rose 600.0% year over year, ahead of the +416.7% change in trailing-twelve-month interest expense. Sequentially, it fell 12.5% from the prior quarter. Over 3 fiscal years it compounded at -17.8% a year.
Context
- Interest expense increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +600.0% holds above the trailing-twelve-month pace of +416.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
CAD · from the income statement
- Latest · FY2025
- 10K CAD
- Year-over-year change
- +42.9%
- 4-year CAGR
- -9.6%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 10K | +42.9% |
| FY2024 | 2024-07-31 | 7K | -50.0% |
| FY2023 | 2023-07-31 | 14K | -22.2% |
| FY2022 | 2022-07-31 | 18K | +20.0% |
| FY2021 | 2021-07-31 | 15K | — |
Interest Expense vs competitors
How HBP.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +416.7% is the highest of 3, against a peer median of +12.6%.
- Over three fiscal years its annual growth of -17.8% compares with a peer median of +42.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $5.88M USD | -38.0% | -0.5% | 10.5% | |
| LTM Apr 2026 | CA$1.68M CAD | +63.2% | +85.6% | — | |
| LTM Apr 2026 | CA$31K CAD | +416.7% | -17.8% | — | |
MSCL.TOSatellos Bioscience Inc. | LTM Mar 2026 | $0 USD | — | — | — |
| LTM Mar 2026 | CA$0 CAD | — | — | — | |
| Peer median (excluding HBP.TO) | — | +12.6% | +42.6% | 10.5% | |
Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jul 2021 | FY2022 Jul 2022 | FY2023 Jul 2023 | FY2024 Jul 2024 | FY2025 Jul 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 173K | 12K | 13K | 14K | 10K |
| Gross Profit | (173K) | (12K) | (13K) | (14K) | (10K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 5.88M | 4.54M | 5.28M | 6.1M | 3.58M |
| Selling, General & Admin | 3.25M | 595K | 299K | 3.26M | 1.84M |
| Operating Expenses | 9.13M | 6.04M | 6.33M | 9.36M | 5.42M |
| Depreciation & Amortization | 173K | 12K | 13K | 14K | 10K |
| EBITDA | (9.46M) | (6.03M) | (6.31M) | (9.38M) | (5.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (9.61M) | (6.54M) | (6.28M) | (9.37M) | (5.43M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 15 | 4K | 47K | 31K | 17K |
| Interest Expense | 15K | 18K | 14K | 7K | 10K |
| Other Income / Expenses | (443K) | (523K) | 36K | (25K) | 192K |
| Income Before Tax | (9.57M) | (6.56M) | (6.29M) | (9.4M) | (5.23M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (1.66M) | (484K) | 14K | (132K) | (28K) |
| Net Income | (7.91M) | (6.08M) | (6.29M) | (9.26M) | (5.21M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.29) | (0.20) | (0.16) | (0.21) | (0.09) |
| EPS (Diluted) | (0.29) | (0.20) | (0.16) | (0.21) | (0.09) |
| Weighted Avg Shares | 27.58M | 29.9M | 38.65M | 44.49M | 55.74M |
| Weighted Avg Shares (Diluted) | 27.58M | 29.9M | 38.65M | 44.49M | 55.74M |
Helix BioPharma Corp.
TSX:HBP.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.